Firmagon (Degarelix Acetate) Patent Expiration, LOE Window & CMS Spending

Firmagon (Degarelix Acetate) by Ferring: FDA Orange Book LOE 2032-04-27, 0 AB generics, $2.4M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorFerring
FDA Application & PathwayN022201 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2032-04-27
Orange Book Patents (*PED Extensions)9 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$2.4M
2024 Medicare Part D Spend$1.2M
2024 Medicaid Spend$1.3M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel